1
|
Palomo L, Xicoy B, Garcia O, Mallo M, Ademà V, Cabezón M, Arnan M, Pomares H, José Larrayoz M, José Calasanz M, Maciejewski JP, Huang D, Shih LY, Ogawa S, Cervera J, Such E, Coll R, Grau J, Solé F, Zamora L. Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. Am J Hematol 2016; 91:185-92. [PMID: 26509444 DOI: 10.1002/ajh.24227] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2015] [Revised: 10/14/2015] [Accepted: 10/26/2015] [Indexed: 12/26/2022]
Abstract
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder with heterogeneous clinical, morphological and genetic characteristics. Clonal cytogenetic abnormalities are found in 20-30% of patients with CMML. Patients with low risk cytogenetic features (normal karyotype and isolated loss of Y chromosome) account for ∼80% of CMML patients and often fall into the low risk categories of CMML prognostic scores. We hypothesized that single nucleotide polymorphism arrays (SNP-A) karyotyping could detect cryptic chromosomal alterations with prognostic impact in these subgroup of patients. SNP-A were performed at diagnosis in 128 CMML patients with low risk karyotypes or uninformative results for conventional G-banding cytogenetics (CC). Copy number alterations (CNAs) and regions of copy number neutral loss of heterozygosity (CNN-LOH) were detected in 67% of patients. Recurrent CNAs included gains in regions 8p12 and 21q22 as well as losses in 10q21.1 and 12p13.2. Interstitial CNN-LOHs were recurrently detected in the following regions: 4q24-4q35, 7q32.1-7q36.3, and 11q13.3-11q25. Statistical analysis showed that some of the alterations detected by SNP-A associated with the patients' outcome. A shortened overall survival (OS) and progression free survival (PFS) was observed in cases where the affected size of the genome (considering CNAs and CNN-LOHs) was >11 Mb. In addition, presence of interstitial CNN-LOH was predictive of poor OS. Presence of CNAs (≥1) associated with poorer OS and PFS in the patients with myeloproliferative CMML. Overall, SNP-A analysis increased the diagnostic yield in patients with low risk cytogenetic features or uninformative CC and added prognostic value to this subset of patients.
Collapse
Affiliation(s)
- Laura Palomo
- MDS Research Group, Institut De Recerca Contra La Leucèmia Josep Carreras; ICO-Hospital Germans Trias I Pujol, Universitat Autònoma De Barcelona; Badalona Spain
- Departament De Bioquímica I Biologia Molecular, Universitat Autònoma De Barcelona; Spain
| | - Blanca Xicoy
- Hematology Service, ICO-Hospital Germans Trias I Pujol, Institut De Recerca Contra La Leucèmia Josep Carreras; Universitat Autònoma De Barcelona; Badalona Spain
| | - Olga Garcia
- Hematology Service, ICO-Hospital Germans Trias I Pujol, Institut De Recerca Contra La Leucèmia Josep Carreras; Universitat Autònoma De Barcelona; Badalona Spain
| | - Mar Mallo
- MDS Research Group, Institut De Recerca Contra La Leucèmia Josep Carreras; ICO-Hospital Germans Trias I Pujol, Universitat Autònoma De Barcelona; Badalona Spain
| | - Vera Ademà
- MDS Research Group, Institut De Recerca Contra La Leucèmia Josep Carreras; ICO-Hospital Germans Trias I Pujol, Universitat Autònoma De Barcelona; Badalona Spain
| | - Marta Cabezón
- Hematology Service, ICO-Hospital Germans Trias I Pujol, Institut De Recerca Contra La Leucèmia Josep Carreras; Universitat Autònoma De Barcelona; Badalona Spain
| | - Montse Arnan
- Hematology Service, ICO-Hospital Duran I Reynals; Barcelona Spain
| | - Helena Pomares
- Hematology Service, ICO-Hospital Duran I Reynals; Barcelona Spain
| | - María José Larrayoz
- CIMA LAB Diagnostics, Department of Biochemistry and Genetics; University of Navarra, Instituto De Investigación Sanitaria De Navarra; Pamplona Spain
| | - María José Calasanz
- CIMA LAB Diagnostics, Department of Biochemistry and Genetics; University of Navarra, Instituto De Investigación Sanitaria De Navarra; Pamplona Spain
| | - Jaroslaw P. Maciejewski
- Department of Translational Hematology and Oncology Research; Taussing Cancer Institute, Cleveland Clinic; Cleveland Ohio
| | - Dayong Huang
- Department of Translational Hematology and Oncology Research; Taussing Cancer Institute, Cleveland Clinic; Cleveland Ohio
| | - Lee-Yung Shih
- Division of Hematology; Chang Gung Memorial Hospital-Linkou, Chang Gung University; Taiwan City Taiwan
| | - Seishi Ogawa
- Department of Pathology and Tumor Biology, Graduate School of Medicine; Kyoto University; Kyoto Japan
| | - Jose Cervera
- Hematology Department; Hospital Universitario La Fe; Valencia Spain
| | - Esperanza Such
- Hematology Department; Hospital Universitario La Fe; Valencia Spain
| | - Rosa Coll
- Hematology Service, ICO Girona Hospital Josep Trueta; Girona Spain
| | - Javier Grau
- Hematology Service, ICO-Hospital Germans Trias I Pujol, Institut De Recerca Contra La Leucèmia Josep Carreras; Universitat Autònoma De Barcelona; Badalona Spain
| | - Francesc Solé
- MDS Research Group, Institut De Recerca Contra La Leucèmia Josep Carreras; ICO-Hospital Germans Trias I Pujol, Universitat Autònoma De Barcelona; Badalona Spain
| | - Lurdes Zamora
- Hematology Service, ICO-Hospital Germans Trias I Pujol, Institut De Recerca Contra La Leucèmia Josep Carreras; Universitat Autònoma De Barcelona; Badalona Spain
| |
Collapse
|